Identification of Ferroptosis-Related Gene Prognostic Signature and HSF1 for Reversing Doxorubicin and Gemcitabine Resistance in Uterine Carcinosarcoma

Abstract

Purpose. Iron metabolism and ferroptosis play crucial roles in the pathogenesis of cancer. In this study, we aim to study the role of ferroptosis-related genes (FRGs) in uterine carcinosarcoma (UCS) and identify potential target for UCS. Methods. Prognostic differentially expressed FRGs were identified of in the TCGA cohort. Integrated analysis, cox regression, and the least absolute shrinkage and selection operator (LASSO) methods of FRGs were performed to construct a multigene signature prognostic model. Moreover, a dataset from Gene Expression Omnibus (GEO) served as an external validation. HSF1 was knockdown in MES-SA and FU-MMT-1 cells, and cell viability, lipid ROS, and intracellular iron level were detected when combined with doxorubicin or gemcitabine. Result. Five FRGs were selected to construct a prognostic model of UCS. The group with high-risk signature score exhibited obviously lower overall survival (OS) than the group with low risk signature score in both TCGA and validated GEO cohorts. Multivariate Cox regression analysis further indicated that the risk score was an independent factor for the prognosis of UCS patients. The high-risk group of UCS has a higher sensitivity in the treatment of doxorubicin and gemcitabine. Knocking down of HSF1 in MES-SA and FU-MMT-1 cells was more sensitive to doxorubicin and gemcitabine via increasing ferroptosis. Conclusions. The five FRGs risk signature prognostic model having a superior and drug sensitivity predictive performance for OS in UCS, and HSF1 is a potential marker sensitive to doxorubicin and gemcitabine in UCS patients.

BUB1 Promotes Gemcitabine Resistance in Pancreatic Cancer Cells by Inhibiting Ferroptosis

“…Ferroptosis is an iron-dependent, programmed cell death process. Extensive research has demonstrated a close association between ferroptosis and GEM resistance in various tumor types, including PDAC [4,8,37]. Although there is currently no research linking BUB1 to ferroptosis, our study found that treatment of PC cells with the ferroptosis inducer Erastin significantly downregulates the expression of BUB1.…”

Harnessing ferroptosis for enhanced sarcoma treatment: mechanisms, progress and prospects

“…SHARPIN, an activator of NF-kappaB, can also induce the ferroptosis of synovial sarcoma cells, and the PGC1α/NRF2/SLC7A11 axis and BNIP3L/NIX-mediated mitophagy is involved in its downstream regulation [ 203 ]. Moreover, in the case of uterine carcinosarcoma, knocking out the ferroptosis-related gene named heat shock factor 1 (HSF1) increased the sensitivity of tumor cells to treatment with adriamycin or gemcitabine, suggesting a potential combination therapy approach [ 204 ]. These findings underscore the versatility of ferroptosis-based treatments across different types of sarcomas.…”

FBXW7 attenuates tumor drug resistance and enhances the efficacy of immunotherapy

“…In uterine cancer sarcoma cells, HSF1 knockdown increases lipid ROS and iron levels, inhibits cell growth, and promotes sensitivity to doxorubicin and gemcitabine treatment. Targeting HSF1 thus reverses drug resistance of doxorubicin and gemcitabine in uterine cancer sarcoma via the ferroptosis pathway ( 26 ).…”